Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report released on Wednesday morning. The brokerage issued a hold rating on the stock.

Aspira Women’s Health Stock Performance

AWH opened at $0.77 on Wednesday. The stock has a fifty day moving average of $0.82 and a 200-day moving average of $1.04. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65. The company has a market capitalization of $12.87 million, a P/E ratio of -0.64 and a beta of 1.39.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.